
Previous zzso zzso zzso clinical trials have demonstrated that both zzso and zzso agents do partially alleviate cancer zzso Pilot information suggested that an anabolic zzso might also improve appetite in patients with cancer zzso The current trial was developed to compare and contrast a zzso agent, a zzso and an anabolic zzso for the treatment of cancer zzso 

Patients suffering from cancer zzso were zzso to receive either zzso zzso 75 zzso zzso zzso zzso 800 zzso orally every day, or zzso 10 zzso orally zzso Patients were observed at monthly intervals to evaluate weight changes and drug zzso Patients also completed questionnaires at baseline and at monthly intervals to evaluate appetite and drug zzso 

zzso resulted in significantly less appetite enhancement and did not have a favorable toxicity zzso zzso zzso and zzso caused a similar degree of appetite enhancement and similar changes in zzso weight status, with zzso trends favoring zzso zzso for both of these zzso zzso was observed to have more zzso toxicity and a higher rate of drug zzso because of toxicity and/or patient refusal than zzso zzso zzso v zzso P zzso zzso zzso had a higher rate of deep zzso zzso than zzso zzso v zzso P zzso 

Whereas zzso clearly seems to be an inferior choice for treating cancer zzso zzso zzso and zzso have similar appetite stimulating efficacy but differing toxicity zzso 

